Literature DB >> 9891022

Characterization of the heparan sulfate and chondroitin sulfate assembly sites in CD44.

B Greenfield1, W C Wang, H Marquardt, M Piepkorn, E A Wolff, A Aruffo, K L Bennett.   

Abstract

Isoforms of CD44 are differentially modified by the glycosaminoglycans (GAGs) chondroitin sulfate (CS), heparan sulfate (HS), and keratan sulfate. GAG assembly occurs at serines followed by glycines (SG), but not all SG are utilized. Seven SG motifs are distributed in five CD44 exons, and in this paper we identify the HS and CS assembly sites that are utilized in CD44. Not all the CD44 SG sites are modified. The SGSG motif in CD44 exon V3 is the only HS assembly site; this site is also modified with CS. HS and CS attachment at that site was eliminated by mutation of the serines in the V3 motif to alanine (AGAG). Exon E5 is the only other CD44 exon that supports GAG assembly and is modified with CS. Using a number of recombinant CD44 protein fragments we show herein that the eight amino acids located downstream of the SGSG site in V3 are responsible for the specific addition of HS to this site. If the eight amino acids located downstream from the first SG site in CD44 exon E5 are exchanged with those located downstream of the SGSG site in exon V3, the SG site in E5 becomes modified with HS and CS. Likewise if the eight amino acids found downstream from the first SG in E5 are placed downstream from the SGSG in V3, this site is modified with CS but not HS. We also show that these sequences cannot direct the modification of CD44 with HS from a distance. Constructs containing CD44 exon V3 in which the SGSG motif was mutated to AGAG were not modified with HS even though they contained other SG motifs. Thus, a number of sequence and structural requirements that dictate GAG synthesis on CD44 have been identified.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9891022     DOI: 10.1074/jbc.274.4.2511

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Distinct kinetic and molecular requirements govern CD44 binding to hyaluronan versus fibrin(ogen).

Authors:  Phrabha S Raman; Christina S Alves; Denis Wirtz; Konstantinos Konstantopoulos
Journal:  Biophys J       Date:  2012-08-08       Impact factor: 4.033

2.  Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.

Authors:  Sukhbir Kaur; Svetlana A Kuznetsova; Michael L Pendrak; John M Sipes; Martin J Romeo; Zhuqing Li; Lijuan Zhang; David D Roberts
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

Review 3.  The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives.

Authors:  Robert Sackstein
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 4.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?

Authors:  Margot Zöller
Journal:  Nat Rev Cancer       Date:  2011-03-10       Impact factor: 60.716

Review 5.  CD44-Targeted Nanocarrier for Cancer Therapy.

Authors:  Prashant Kesharwani; Rahul Chadar; Afsana Sheikh; Waleed Y Rizg; Awaji Y Safhi
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

Review 6.  Rheostatic signaling by CD44 and hyaluronan.

Authors:  Ellen Puré; Richard K Assoian
Journal:  Cell Signal       Date:  2009-01-13       Impact factor: 4.315

Review 7.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

8.  A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer.

Authors:  Vinata B Lokeshwar; Daley S Morera; Sarrah L Hasanali; Travis J Yates; Marie C Hupe; Judith Knapp; Soum D Lokeshwar; Jiaojiao Wang; Martin J P Hennig; Rohitha Baskar; Diogo O Escudero; Ronny R Racine; Neetika Dhir; Andre R Jordan; Kelly Hoye; Ijeoma Azih; Murugesan Manoharan; Zachary Klaassen; Sravan Kavuri; Luis E Lopez; Santu Ghosh; Bal L Lokeshwar
Journal:  Clin Cancer Res       Date:  2020-02-24       Impact factor: 12.531

9.  A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor.

Authors:  Shlomo Nedvetzki; Itshak Golan; Nathalie Assayag; Erez Gonen; Dan Caspi; Micha Gladnikoff; Avner Yayon; David Naor
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

10.  The Role of Hyaluronan and CD44 in the Pathogenesis of Lupus Nephritis.

Authors:  Susan Yung; Tak Mao Chan
Journal:  Autoimmune Dis       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.